Please login to the form below

Not currently logged in
Email:
Password:

Deltyba

This page shows the latest Deltyba news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

Otsuka's recently-approved tuberculosis therapy Deltyba is effective even in complicated infections caused by extensively drug-resistant (XDR) strains of the bacterium, says a new study. ... Deltyba was approved for marketing last year in Europe, joining

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    Otsuka wins approval for TB drug Deltyba. Second drug approved by EC in 2014 for multidrug resistant tuberculosis. ... Otsuka challenged this recommendation, and the CHMP later recommended Deltyba after a re-examination of the information supplied by

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    While wholly novel drugs to treat multidrug-resistant TB have been thin on the ground, last year saw a brace of new therapies approved in the EU, namely Otsuka's Deltyba

  • EMA to expand orphan drug HTA collaboration EMA to expand orphan drug HTA collaboration

    Deltyba and Lucane Pharma's Lucane both for multi-drug resistant tuberculosis.

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    The nitro-dihydroimidazo-oxazole derivative Delamanid (Deltyba; Otsuka Pharmaceutical) inhibits mycolic acid synthesis and thus the formation of the mycobacterial cell envelope.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics